| |
|
|
|
|
|
Aciphex®, discovered and developed by Eisai, is a proton pump inhibitor that suppresses acid production in the cells of the stomach lining. Aciphex® was approved by the FDA in 1999 for the healing of erosive gastroesophageal reflux disease (GERD), maintenance of healed erosive GERD, healing of duodenal ulcers and treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. It also is approved for treatment of daytime and nighttime heartburn and other symptoms associated with GERD. According to the American College of Gastroenterology, approximately 19 million Amer
|
Company:
Date:
May 03, 2010
|
|
|
|
|
|
|
|
|
|
Efficacy : inhibits platelet aggregation and is a direct arterial vasodilator
form : Cilostazol
Substances : Treatment of intermittent claudication
|
Company:
Date:
May 03, 2010
|
|
|
|
|
|
|
|
|
|
Efficacy : aminoglycoside antibiotic
form : Gentamicin sulfate
Substances : treat many types of bacterial infections, particularly those caused by Gram-negative bacteria
|
Company:
Date:
May 03, 2010
|
|
|
|
|
|
|
|
|
|
pneumonia, bronchitis, scarlet fever, bacterial endocarditis, pyelonephritis, cystitis, urethritis, peritonitis, osteomyelitis, secondary infections in injury and post-operation, typhoid fever, infection after tooth extraction
|
Company:
Date:
May 03, 2010
|
|
|
|
|
|
|
|
|
|
Aricept®, discovered and developed by Eisai and approved by the U.S. Food and Drug Administration (FDA) in 1996, is a once-a-day product to treat mild, moderate and severe Alzheimer's disease. Studies showed Aricept® treats Alzheimer's symptoms, slowing the loss of overall function and improving cognition. About 5 million people in the United States have Alzheimer's disease, a progressive brain disease that gradually destroys a person's memory and ability to learn, reason, make judgments, communicate and carry out daily activities. While there is no cure, the prescription medicine Aricept® is
|
Company:
Date:
May 03, 2010
|
|
|
|
|
|
|
|
|
|
White to slightly yellowish crystalline powder
|
Company:
Date:
May 03, 2010
|
|
|
|
|
|
|
|
|
|
Lower respiratory tract infections, Other respiratory tract infection, Urogenital tract infections, Skin and soft tissue infections, Intestinal infections
|
Company:
Date:
May 03, 2010
|
|
|
|
|
|
|
|
|
|
Respiratory, genitourinary, skin & soft tissue infections, intestinal infection, etc
|
Company:
Date:
May 03, 2010
|
|
|
|
|
|
|
|
|
|
Septicemia, respiratory infection, secondary infection in chronic respiratory disease, cholecystitis, cholangitis, urinary tract infection, intrauterine infection, adnexitis, periuterine infection, para-mandibula cellulitis, prevention of post-operative infection
|
Company:
Date:
May 03, 2010
|
|
|
|
|
|
|
|
|
|
Microbiology
Staphylococcus, Streptococcus pyogenes(groupA-¥â hemolytics), Streptococcus pneumoniae, E.coli, Bacillus pneumoniae, Proteus mirabilis
¡¤ Indications
Septicemia, pneumonia bronchitis, secondary infection in chronic respirator
|
Company:
Date:
May 03, 2010
|
|
|
|
|
|